Was Rahul a UK citizen? EC postpones his nomination paper scrutiny to April 22

New Delhi, Jul 5: With highest-ever single-day spike of 24,850 COVID-19 cases in 24 hours, India's coronavirus count stood at 6,73,165, informed the Union Ministry of Health and Family Welfare on Sunday.

Out of the total cases, 2,44,814 are active cases. On the other hand, India's cured/discharged patients count crossed the 4 lakh mark with 4,09,082 patients cured/discharged and one patient migrated.

As many as 613 deaths due to coronavirus were reported in the country in the last 24 hours taking the death toll in the country to 19,268.

Meanwhile, the ministry said that collective and focused efforts for containment and management of COVID-19 by the government of India along with the States/UTs have led to the number of recovered cases among COVID-19 patients rise to 4,09,082 as of today.

"During the last 24 hours, a total of 14,856 COVID-19 patients have been cured. So far, there are 1,64,268 more recovered patients than COVID-19 active cases. This takes the national recovery rate amongst COVID-19 patients to 60.77 per cent," the ministry said.

"With 786 labs in government sector and 314 private labs, there are as many as 1,100 labs in India," it added.

As per the Health Ministry, coronavirus cases in Maharashtra -- the worst affected state from the infection -- has breached the 2 lakh mark with 2,00,064 cases including 8,671 deaths.

Tamil Nadu reported 4,150 fresh COVID-19 cases and 60 deaths today, taking total cases to 1,11,151 and death toll to 1,510. Number of active cases stands at 46,860, according to the State Health Department.

Delhi's coronavirus tally nears the 1 lakh mark with 99,444 cases and the number of people succumbing to the virus stands at 3,067 in the national capital. As many as 9,873 RT-PCR tests and 13,263 rapid antigen tests were conducted today in Delhi. Total tests done so far stands at 6,43,504.

Meanwhile, Indian Council of Medical Research informed that the total number of samples tested up to July 4 is 97,89,066 of which 2,48,934 samples were tested yesterday.

There were seven new COVID-19 cases in the last 24 hours in Chandigarh, taking total cases to 466 including 395 recoveries and six deaths.
Himachal Pradesh Health Department informed that COVID-19 cases reach 1,048 in the state, of which, 309 cases are active and 715 have recovered.

Andhra Pradesh has reported 998 new COVID-19 cases and 14 deaths in the last 24 hours, according to a media bulletin released by AP state COVID nodal officer.

A total of 1,155 COVID-19 cases were reported in the last 24 hours in Uttar Pradesh on Sunday, taking the total number of active cases to 8,161 in the state, an official said. According to the official data, a total of 18,761 people have been cured while 785 people have died due to the virus in the state.

Eighteen more personnel of Indo-Tibetan Border Police (ITBP) tested positive for COVID-19 in the last 24 hours. There are total 151 active cases and 270 have recovered till date.

While, in the last 24 hours, 36 more Border Security Force (BSF) personnel tested positive for COVID-19 and 33 have recovered. There are 526 active cases and 817 personnel have recovered till date.

In Rajasthan, 224 fresh COVID-19 positive cases and 6 deaths were reported today. The total number of cases rose to 19,756 including 3,640 active cases and 453 deaths.

Odisha reported 469 new COVID19 positive cases in the last 24 hours, taking the total number of positive cases in the state to 9,070 including 5,934 recovered cases and 3,090 active cases, according to the health department.

Uttarakhand reported 31 new COVID-19 cases in the last 24 hours, taking total cases to 3,124. Recovery rate among COVID-19 patients stands at 80.79 per cent.

New Delhi, Jan 12: A fact-finding committee of the Congress on the JNU violence on Sunday said the January 5 attack inside the university campus was "state-sponsored" and recommended Vice Chancellor M Jagadesh Kumar be dismissed and criminal investigation initiated against him.

The Congress had appointed a four-member fact-finding committee to carry out a detailed inquiry into the violence at the Jawaharlal Nehru University (JNU).

Sushmita Dev, member of the committee, said the committee recommended that Kumar should be dismissed immediately and all the appointments in faculty should be probed and independent inquiry should take place.

"Criminal investigation must take place against the VC and faculty members and the security company," the Mahila Congress chief said.

"It is clear that the attack on JNU campus was state-sponsored," Dev said.

She also demanded a complete rollback of the JNU fee hike.

The other members of the fact-finding committee are Hibi Eden, MP and former NSUI president, Syed Naseer Hussain, MP and former president of JNU NSUI and Amrita Dhawan, a former NSUI president and ex-DUSU president.

On January 5 night, masked people armed with rods and sticks stormed the JNU campus and assaulted students and faculty members, and vandalised property, leaving several people injured.

Leftist outfits and the RSS-affiliated Akhil Bharatiya Vidyarthi Parishad (ABVP) blamed each other for the violence.

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.